Please assess the completion status of the following clinical trial:

Trial Title: Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEB

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. The subject or legally appointed and authorized representative must have read, understood and signed an Institutional Review Board/Ethics Committee (IRB/EC) approved Informed Consent or Assent Form and must be able to and willing to follow study procedures and instructions.~2. Age ≥ 6 months and older at the time of Informed Consent.~3. Clinical diagnosis of the Dystrophic Epidermolysis Bullosa.~4. Confirmation of DEB diagnosis (either DDEB or RDEB) by genetic testing including COL7A1.~5. Two (2) cutaneous wounds meeting the following criteria:~   1. Location: similar in size, located in similar anatomical regions, and have similar appearance~  2. Appearance: clean with adequate granulation tissue, excellent vascularization, and do not appear infected.~6. Subjects and caregivers who, in the opinion of the Investigator, are able to understand the study, co-operate with the study procedures and are willing to return to the clinic for all the required follow-up visits.~7. Male or Female of childbearing potential must use a reliable birth control method throughout the duration of the study and for three (3) months post last dose of B-VEC.~8. Negative pregnancy test at Visit 1 (Week 1), if applicable.~Exclusion Criteria:~1. Medical instability limiting ability to travel to the Investigative Center.~2. Diseases or conditions that could interfere with the assessment of safety and efficacy of the study treatment and compliance of the subject with study visits/procedures, as determined by the Investigator.~3. Current evidence or a history of squamous cell carcinoma in the area that will undergo treatment.~4. Subjects actively receiving chemotherapy or immunotherapy at Visit 1 (Week 1).~5. Active drug or alcohol addiction as determined by the Investigator.~6. Hypersensitivity to local anesthesia (lidocaine/prilocaine cream).~7. Participation in an interventional clinical trial within the past three (3) months (not including BVEC administration).~8. Receipt of a skin graft in the past three (3) months.~9. Pregnant or nursing women.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- B-VEC (Type: EXPERIMENTAL): Topical gel of non-integrating, replication-incompetent HSV-1 expressing the human collagen VII protein
- Placebo (Type: PLACEBO_COMPARATOR): Matching masked inactive topical gel

Based on this trial design, predict the completion outcome and termination type (if applicable).